{
  "id": 18695572,
  "title": "aim immunoTech CEO Equels buys $3,166 in company stock",
  "url": "https://urgent.news/2026/11/07/aim-immunotech-ceo-equels-buys-3-166-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T10:30:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/aim-immunotech-ceo-equels-buys-3166-in-company-stock-93CH-5009813"
  },
  "original_language": "en",
  "account": "AIM ImmunoTech CEO Thomas K. Equels made a significant stock purchase on November 6, 2026, acquiring 20,299 shares at a total cost of $3,166. This equates to a purchase price of $0.156 per share. As a result of this transaction, Mr. Equels now holds a beneficial ownership of 210,046 shares of AIM ImmunoTech common stock. The company's stock price has been trading near its 52-week low of $0.15, marking a 91% decline over the past year. According to InvestingPro, the stock's fair value is estimated at $0.20, suggesting it may be undervalued at the current price. AIM ImmunoTech's market capitalization stands at $4.63 million. In addition to this stock purchase, the company has recently published an article by its CEO in Breaking Defense, discussing the potential of their drug, Ampligen, as a broad-spectrum antiviral therapeutic for diseases like Ebola and COVID-19. The article includes forward-looking statements regarding Ampligen's potential applications and future clinical trials. AIM ImmunoTech has noted that the preclinical findings mentioned in the article do not equate to FDA approval or confirm clinical efficacy in humans. The company has provided a copy of the article to the SEC as an exhibit, demonstrating their commitment to transparency regarding potential advancements in Ampligen's applications.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}